Top Page
China Bozza Development Holdings Limited
(1069)
China Bozza Development Holdings Limited (1069) vs. iShares MSCI Hong Kong ETF (EWH)
China Bozza Development Holdings Limited Business Overview & Revenue Model
China Bozza Development Holdings Limited Financial Statement Overview
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 59.70M | 47.61M | 58.72M | 6.76M | 6.67M | 54.25M |
| Gross Profit | 916.00K | 1.90M | 11.51M | 0.00 | 6.67M | 34.81M |
| EBITDA | -22.17M | 208.39M | -42.17M | -9.85M | -48.36M | 18.65M |
| Net Income | 3.57M | 200.01M | -10.80M | -18.90M | -268.54M | -340.48M |
Balance Sheet | ||||||
| Total Assets | 191.09M | 178.17M | 140.64M | 93.52M | 491.54M | 588.51M |
| Cash, Cash Equivalents and Short-Term Investments | 2.68M | 3.23M | 4.33M | 1.11M | 134.00K | 3.18M |
| Total Debt | 115.23M | 119.11M | 356.77M | 321.97M | 333.44M | 313.10M |
| Total Liabilities | 166.22M | 165.20M | 457.35M | 400.15M | 369.48M | 336.27M |
| Stockholders Equity | 24.87M | 12.96M | -316.71M | -306.63M | 122.06M | 252.24M |
Cash Flow | ||||||
| Free Cash Flow | 841.00K | 28.63M | 22.16M | -466.00K | -5.58M | -9.97M |
| Operating Cash Flow | 27.33M | 28.86M | 23.44M | -466.00K | -5.58M | -9.73M |
| Investing Cash Flow | -26.54M | -26.49M | -23.26M | 2.00K | -410.00K | 283.00K |
| Financing Cash Flow | 365.00K | -3.47M | 3.04M | -249.00K | -3.29M | 7.13M |
China Bozza Development Holdings Limited Technical Analysis
China Bozza Development Holdings Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$1.82B | 9.72 | 3.56% | 2.94% | -5.66% | -56.96% | |
| ― | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
| ― | HK$180.00M | 7.02 | 2.13% | 5.95% | 0.80% | 81.27% | |
| ― | HK$268.77M | 15.57 | 11.34% | ― | -9.44% | ― | |
| ― | HK$4.55B | ― | ― | ― | -60.85% | -2065.97% | |
| ― | HK$46.32M | 1.55 | 75.10% | ― | 88.72% | -91.59% | |
| ― | HK$60.92M | 27.06 | 0.44% | ― | -0.53% | ― |
China Bozza Development Holdings Limited Corporate Events
China Bozza Development Holdings Limited has successfully completed the placement of 17,000,000 new shares under a general mandate, representing approximately 16.52% of the company’s enlarged share capital. The placement raised net proceeds of approximately HK$4.63 million, which will be allocated towards rental expenses, staff costs, and professional fees. This strategic move aims to strengthen the company’s financial position and operational capabilities without altering the substantial shareholder structure.
China Bozza Development Holdings Limited has announced a placing agreement with Cheong Lee Securities Limited to issue up to 17,000,000 new shares at HK$0.28 each, representing a significant discount to recent trading prices. The net proceeds of approximately HK$4.63 million will be used for general working capital, potentially impacting the company’s financial flexibility and market positioning.
China Health Technology Group Holding Company Limited announced the successful passing of a resolution at its Extraordinary General Meeting held on July 4, 2025, approving a share consolidation. The share consolidation will take effect on July 8, 2025, with new share certificates issued in gold color, impacting trading and settlement processes. This move is expected to streamline the company’s share structure, potentially enhancing market perception and operational efficiency.
China Health Technology Group Holding Company Limited has announced an extraordinary general meeting (EGM) to discuss a proposed share consolidation. The company plans to consolidate every ten issued and unissued ordinary shares into one share, which could impact shareholder value and market perception. The move is subject to approval from the Hong Kong Stock Exchange and compliance with Cayman Islands laws. This consolidation aims to streamline the company’s share structure, potentially enhancing its market positioning and operational efficiency.
China Bozza Development Holdings Limited has announced a proposed share consolidation and change in board lot size. The company plans to consolidate every ten existing shares into one consolidated share, reducing the number of shares in issue from 859,242,204 to 85,924,220, while maintaining the authorized share capital at HK$100,000,000. Additionally, the board lot size for trading on the Stock Exchange will change from 16,000 existing shares to 10,000 consolidated shares. This move is intended to streamline the company’s share structure without affecting its financial position or shareholder rights.
China Health Technology Group Holding Company Limited has entered into a strategic cooperation memorandum with Heilongjiang Jianzhi Tang Biotechnology Co., Ltd. to collaborate on the research, development, and sales of lingzhi products and health supplements. This partnership aims to leverage Jianzhi Tang’s technological strengths to expand the company’s health product offerings, enhancing business diversification and creating new profit growth drivers. The collaboration is expected to improve the company’s financial performance and profitability, benefiting shareholders. The memorandum serves as a framework for future agreements, with both parties planning market analysis and industry research to support the initiative.